PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia

10.36837/chapman.000294 ◽

2021 ◽

Author(s):

◽

Kamron Lotfi

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics ◽

10.1007/s40273-019-00812-6 ◽

2019 ◽

Vol 37 (9) ◽

pp. 1177-1193 ◽

Cited By ~ 6

Author(s):

Thomas E. Delea ◽

Xinke Zhang ◽

Jordan Amdahl ◽

Diana Boyko ◽

Franziska Dirnberger ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

The United States ◽

Adult Patients ◽

Cell Precursor ◽

Inotuzumab Ozogamicin

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Japan

Transplantation and Cellular Therapy ◽

10.1016/j.jtct.2020.12.023 ◽

2020 ◽

Author(s):

Shiho Wakase ◽

Takanori Teshima ◽

Jie Zhang ◽

Qiufei Ma ◽

Yoko Watanabe ◽

...

Keyword(s):

Cost Effectiveness ◽

Young Adult ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Adult Patients ◽

Effectiveness Analysis ◽

Cell Acute Lymphoblastic Leukemia

PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.255 ◽

2020 ◽

Vol 23 ◽

pp. S444

Author(s):

I. van Oostrum ◽

K. De Lameillieure ◽

T.A. Russell-Smith

Keyword(s):

The Netherlands ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

Inotuzumab Ozogamicin

PIH8 Cost-Effectiveness Analysis Of Dasatinib Versus Imatinib In Treating Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients In China

Value in Health ◽

10.1016/j.jval.2021.04.526 ◽

2021 ◽

Vol 24 ◽

pp. S100

Author(s):

W. Cao ◽

Y. Yu ◽

L. Shi ◽

Y. Qiu ◽

H. Zhang ◽

...

Keyword(s):

Cost Effectiveness ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Effectiveness Analysis ◽

Philadelphia Chromosome Positive

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.22936 ◽

2011 ◽

Vol 57 (2) ◽

pp. 231-239 ◽

Cited By ~ 26

Author(s):

Jennifer R. Donnan ◽

Wendy J. Ungar ◽

Maria Mathews ◽

Rebecca L. Hancock-Howard ◽

Proton Rahman

Keyword(s):

Cost Effectiveness ◽

Lymphoblastic Leukemia ◽

Thiopurine Methyltransferase ◽

PCN19 COST-EFFECTIVENESS ANALYSIS OF CLOFARABINE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

Value in Health ◽

10.1016/s1098-3015(10)75346-8 ◽

2009 ◽

Vol 12 (7) ◽

pp. A496

Author(s):

K Rely ◽

EG Salinas ◽

KA Pierre ◽

MEA Dorantes

Keyword(s):

Cost Effectiveness ◽

Lymphoblastic Leukemia ◽

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Drug Design Development and Therapy ◽

10.2147/dddt.s150317 ◽

2018 ◽

Vol Volume 12 ◽

pp. 2293-2300 ◽

Cited By ~ 20

Author(s):

Ilana R Yurkiewicz ◽

Lori Muffly ◽

Michaela Liedtke

Keyword(s):

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Drug Conjugate

What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?

Journal of Clinical Oncology ◽

10.1200/jco.2018.79.3570 ◽

2018 ◽

Vol 36 (32) ◽

pp. 3183-3185 ◽

Cited By ~ 3

Author(s):

Christopher R. Flowers ◽

Scott D. Ramsey

Keyword(s):

Cost Effectiveness ◽

T Cell ◽

Cell Therapy ◽

Chimeric Antigen Receptor ◽

Lymphoblastic Leukemia ◽

Antigen Receptor ◽

T Cell Therapy ◽

PCN73 COST-EFFECTIVENESS OF BLINATUMOMAB VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A CANADIAN HEALTHCARE SECTOR PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2020.04.1575 ◽

2020 ◽

Vol 23 ◽

pp. S36

Author(s):

T.E. Delea ◽

K. Raman ◽

D. Boyko ◽

A. Moynahan ◽

F. Dirnberger ◽

...

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Standard Of Care ◽

Adult Patients ◽

Healthcare Sector ◽

Cell Precursor ◽

Canadian Healthcare